Hippocampal GPR35 is involved in the depression-like behaviors induced by inflammation and mediates the antidepressant effects of fluoxetine in mice
Brain, Behavior, and Immunity · 2025-05 · 126 · 189-213
DOI: 10.1016/j.bbi.2025.02.010 ↗Kurz gefasst
Fachartikel in der Zeitschrift Brain, Behavior, and Immunity, 2025-05. Verfasst von Xu Kang und 7 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Anhui Medical University, The Key Laboratory of Major Autoimmune Diseases of Anhui Province, Hefei 230032, China; The Key Laborat…. Hauptthemen laut MEDLINE: Receptors, G-Protein-Coupled, Hippocampus, Fluoxetine, Depression. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 84 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Anhui Province.
Themen: Depression
Abstract (Originalsprache)
BACKGROUND: Neuroinflammation plays a pivotal role in the pathogenesis of depression. G protein-coupled receptor 35 (GPR35) is expressed in the brain and plays a role in regulating inflammatory processes. However, its specific role in depression remains unclear. Herein, we investigate the role of GPR35 in depressive behaviors induced by lipopolysaccharide (LPS) in mice. METHODS: We employed an LPS-induced depression mouse model and conducted behavioral tests, molecular analyses, and morphological assessments, along with chemogenetic techniques, to investigate the role of GPR35 in depression. RESULTS: Our results showed a significant increase in GPR35 expression in the brain of LPS-treated mice. Both pharmacological inhibition and genetic knockdown of GPR35 alleviated LPS-induced depressive-like behaviors by mitigating neuroinflammation, oxidative stress, synaptic plasticity deficits, and TLR4/NF-κB signaling in mice. Conversely, pharmacological activation of GPR35 notably exacerbated LPS-induced depressive-like behaviors in mice. Additionally, the GPR35 antagonist ML-145 effectively prevented LPS-induced inflammation responses in BV-2 microglia cells. Moreover, fluoxetine treatment effectively mitigated the upregulation of hippocampal GPR35 expression induced by LPS in mice. However, administration of the GPR35 agonist zaprinast reversed the antidepressant effects of fluoxetine. Chemogenetic activation of hippocampal glutamatergic neurons attenuated LPS-induced depression-like behaviors, accompanied by decreased GPR35 expression. CONCLUSION: Hippocampal GPR35 is closely associated with depressive behaviors in the inflammatory model, highlighting its potential as a therapeutic target for antidepressant drug development.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Pharmacy, Anhui Medical University, The Key Laboratory of Major Autoimmune Diseases of Anhui Province, Hefei 230032, China; The Key Laboratory of Anti-inflammatory and Immune Medicines, Anhui Medical Universit…
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Anhui Province
Zitieren
APA
Kang, X., Xie, Z., Yang, Y., Wu, L., Xu, H., Zhang, S., Liang, Y., & Wu, X. (2025). Hippocampal GPR35 is involved in the depression-like behaviors induced by inflammation and mediates the antidepressant effects of fluoxetine in mice. Brain, Behavior, and Immunity, 126, 189-213. https://doi.org/10.1016/j.bbi.2025.02.010
Vancouver
Kang X, Xie Z, Yang Y, Wu L, Xu H, Zhang S, et al. Hippocampal GPR35 is involved in the depression-like behaviors induced by inflammation and mediates the antidepressant effects of fluoxetine in mice. Brain, Behavior, and Immunity. 2025;126:189-213. doi:10.1016/j.bbi.2025.02.010
BibTeX
@article{Kang2025,
author = {Kang, Xu and Xie, Zhi and Yang, Yan and Wu, Lei and Xu, Heng and Zhang, Shuai and Liang, YuSheng and Wu, Xian},
title = {Hippocampal GPR35 is involved in the depression-like behaviors induced by inflammation and mediates the antidepressant effects of fluoxetine in mice},
journal = {Brain, Behavior, and Immunity},
year = {2025},
volume = {126},
pages = {189--213},
doi = {10.1016/j.bbi.2025.02.010}
}
EUVIMED